Due to the large patient base, the global cancer biologic therapy market will experience significant growth. Other factors driving the growth of this market include the growing number of cancers, increasing impact of biosimilars, continued patent expiry of drugs against cancer, and growing demand for targeted and biological drug therapy.
Biological therapy is the use of a living organism substance that has been derived from living organisms, or laboratory-produced variations. It can be used to treat a specific disease. Biological therapies typically include interleukins and interferons as well as monoclonal antibodies and vaccines. Biological therapy uses the body's immune system to combat cancer. Some therapies use antibodies, while others use bacteria or vaccines to stimulate the immune system.
However, there are other factors that can hinder the growth of this market, such as high drug development costs, adverse side effects of chemotherapy for cancer, failure rate in treatment and strict government guidelines.
Global cancer biologic therapy market is divided on the basis product, distribution channel, and geography. The global market can be classified based on product: Monoclonal antibodies (Vaccines), Cancer growth blockers (Cancer growth factors), Blood cell growth factors (Blood cell growth factors) and Cytokines.
The " Monoclonal antibodies" segment can be further sub-classified into Conjugated monoclonal, Naked, and Bispecific monoclonal antibody segments. The "Vaccines†segment is further sub-classified as Preventive vaccines, and Therapeutic vaccines. The "Cancer growth inhibitors" segment can be further sub-categorized as Tyrosine kinase, Proteasome and mTOR inhibitors. Filgrastim, Lenograstim, and Filgrastim are further sub-classified as Blood cell growth factors. The "Cytokines†segment is further sub-classified as Interferons or Interleukins.
The global market for cancer biologic therapy is divided into three categories: Hospital pharmacies (Retail pharmacies), and Mail order pharmacies (Mail order pharmacies). The global market can be divided into North America, Latin America and Western Europe, Eastern Europe and Asia Pacific, with the exception of Japan, Middle East and Africa.
North America includes the U.S.A. and Canada. Latin America includes Brazil and Mexico. The Western European region includes Germany, Italy and Spain. It also includes France, Germany, England, Spain and France. The Eastern European region includes Russia, Poland, and Rest of Eastern Europe. Asia Pacific Excludes Japan includes China, India ASEAN, Australia, & New Zealand. Middle East and Africa includes GCC, S. Africa and N. Africa and Rest of MEA.
Geographically, North America holds a large share of the global market for cancer biologic therapy. Europe and Asia Pacific are closely following the North American market. Rising R&D investments, government initiatives, rising disposable income, high-quality cancer treatment facilities, and an increasing number of insurance policies for serious illnesses are some of the factors driving the North American market's growth.
Asia Pacific is expected to grow at the fastest rate due to increasing incidence of cancer, large patient pools, improved healthcare facilities, and so forth. Japan is the largest contributor to the Asia Pacific cancer treatment market. Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche AG, Novartis International AG, Merck & Co., Inc., GlaxoSmithKline Plc, Eli Lilly, Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., and others are some of the key players driving the growth of the global market for cancer biological therapy.
Up Market Research published a new report titled “Cancer Biological Therapy Market research report which is segmented by Product (Monoclonal Antibodies, Cancer Growth Blockers, Vaccines), by Distribution Channel (Retail & Mail Order Pharmacies, Hospital), By Players/Companies Bristol-Myers Squibb, Amgen Inc, Novartis International AG, Inc, Inc, Inc, GlaxoSmithKline Plc, Seattle Genetics, etc, Spectrum Pharmaceuticals, Celgene Corporation, Eli Lilly, Merck & Co, F Hoffmann-La Roche AG”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Attributes | Report Details |
Report Title | Cancer Biological Therapy Market Research Report |
By Product | Monoclonal Antibodies, Cancer Growth Blockers, Vaccines |
By Distribution Channel | Retail & Mail Order Pharmacies, Hospital |
By Companies | Bristol-Myers Squibb, Amgen Inc, Novartis International AG, Inc, Inc, Inc, GlaxoSmithKline Plc, Seattle Genetics, etc, Spectrum Pharmaceuticals, Celgene Corporation, Eli Lilly, Merck & Co, F Hoffmann-La Roche AG |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 239 |
Number of Tables & Figures | 168 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Product (Monoclonal Antibodies, Cancer Growth Blockers, Vaccines), by Distribution Channel (Retail & Mail Order Pharmacies, Hospital).
Cancer Biological Therapy Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Cancer Biological Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Cancer Biological Therapy Market Report:
Some other reports from this category!